

DEPARTMENT OF DEFENSE

Department of the Army

Intent to Grant an Exclusive License for U.S. Government-Owned Invention

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Paul Michaels, Director of the Office of
Research & Technology Applications, (301) 619-4145.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,
royalty-bearing, revocable license to “purified, recombinant, catalytically inactive botulinum
neurotoxin holoproteins (ciBoNT) representing serotypes A-F produced in transgenic strains of
the methylotrophic yeast *Pichia pastoris*, and *Pichia pastoris* cell lines expressing the same
ciBoNTs, in their capacity as producers of the ciBoNTs only” to Mapp Biopharmaceutical, Inc.,
having its principal place of business at 6160 Lusk Blvd. # C200, San Diego, CA 92121.

Anyone wishing to object to grant of this license can file written objections along with
supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).

The deadline to receive comments is December 21, 2020